CLINICAL TRIALS PROFILE FOR AKINETON
✉ Email this page to a colleague
All Clinical Trials for AKINETON
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00495183 ↗ | Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence | Unknown status | Hospital Universitari Vall d'Hebron Research Institute | Phase 4 | 2009-01-01 | The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied. Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 10 days in an in-hospital setting. |
NCT01048138 ↗ | Use of Biperiden for the Prevention of Post-traumatic Epilepsy | Recruiting | Cristália Produtos Químicos Farmacêuticos Ltda. | Phase 3 | 2018-01-31 | There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy. |
NCT01048138 ↗ | Use of Biperiden for the Prevention of Post-traumatic Epilepsy | Recruiting | University of Sao Paulo | Phase 3 | 2018-01-31 | There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy. |
NCT01048138 ↗ | Use of Biperiden for the Prevention of Post-traumatic Epilepsy | Recruiting | Federal University of São Paulo | Phase 3 | 2018-01-31 | There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AKINETON
Condition Name
Clinical Trial Locations for AKINETON
Clinical Trial Progress for AKINETON
Clinical Trial Phase
Clinical Trial Sponsors for AKINETON
Sponsor Name